HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hirotoshi Utsunomiya Selected Research

Pepsinogen A (Pepsinogen)

3/2014Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
12/2012Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis.
3/2010Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion.
12/2009Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels.
8/2008Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels.
4/2008Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hirotoshi Utsunomiya Research Topics

Disease

17Neoplasms (Cancer)
06/2014 - 01/2002
9Cardiovascular Diseases (Cardiovascular Disease)
08/2013 - 11/2002
6Hypertension (High Blood Pressure)
01/2023 - 09/2005
6Infections
04/2022 - 01/2007
6Insulin Resistance
11/2018 - 10/2005
6Atherosclerosis
08/2013 - 09/2005
5Vascular Remodeling
01/2023 - 11/2002
5Stomach Neoplasms (Stomach Cancer)
12/2012 - 08/2005
5Inflammation (Inflammations)
12/2012 - 08/2005
3Fatty Liver
10/2019 - 08/2012
3Type 2 Diabetes Mellitus (MODY)
10/2019 - 02/2007
3Hyperglycemia
10/2019 - 05/2009
3Atrophy
03/2014 - 04/2008
3Gastritis
03/2014 - 03/2010
3Breast Neoplasms (Breast Cancer)
10/2010 - 01/2002
2Obesity
11/2018 - 05/2009
2Hyperlipidemias (Hyperlipidemia)
01/2014 - 02/2007
2Fibrosis (Cirrhosis)
08/2012 - 09/2005
2Adenocarcinoma
07/2012 - 10/2002
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
04/2012 - 11/2005
2Hypertrophy
05/2011 - 10/2005
2Neoplasm Metastasis (Metastasis)
10/2010 - 11/2005
2Carcinoma (Carcinomatosis)
10/2010 - 03/2009
2Liver Diseases (Liver Disease)
10/2008 - 05/2007
2Carcinogenesis
11/2007 - 08/2005
2Cholestasis
07/2007 - 05/2007
2Vascular System Injuries
01/2006 - 10/2005
1Hyperplasia
04/2022
1Food Hypersensitivity (Food Allergy)
04/2022
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
04/2022
1Anaphylaxis (Anaphylactic Shock)
10/2020
1Hypersensitivity (Allergy)
10/2020
1Osteoporosis
10/2019
1Gastroesophageal Reflux (GERD)
07/2015
1Poliomyelitis (Polio)
10/2014
1Female Infertility
06/2014
1Diabetes Mellitus
01/2014
1Cholecystitis
01/2012
1Gallbladder Neoplasms (Gallbladder Cancer)
01/2012

Drug/Important Bio-Agent (IBA)

6Pepsinogen A (Pepsinogen)IBA
03/2014 - 04/2008
5Angiotensin IIIBA
01/2023 - 10/2005
4Glucose (Dextrose)FDA LinkGeneric
01/2023 - 01/2014
4Indicators and Reagents (Reagents)IBA
10/2014 - 10/2002
4Reactive Oxygen Species (Oxygen Radicals)IBA
11/2009 - 11/2002
3Insulin (Novolin)FDA Link
10/2019 - 01/2006
2Calcitonin (Calcitonin, Eel)FDA LinkGeneric
10/2019 - 11/2018
2AdiponectinIBA
11/2018 - 10/2005
2LipidsIBA
11/2018 - 01/2014
2AcidsIBA
07/2015 - 08/2009
2Antiviral Agents (Antivirals)IBA
10/2014 - 04/2007
2Estradiol (Delestrogen)FDA LinkGeneric
06/2014 - 05/2008
2colestimideIBA
01/2014 - 02/2007
2ErbB Receptors (EGF Receptor)IBA
08/2013 - 12/2002
2ethyl acetateIBA
08/2013 - 05/2011
2Fluorouracil (Carac)FDA LinkGeneric
07/2012 - 01/2002
2Death-Associated Protein KinasesIBA
07/2012 - 04/2012
2Etodolac (Lodine)FDA LinkGeneric
03/2010 - 08/2005
2Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA
03/2010 - 08/2005
2Irinotecan (Camptosar)FDA LinkGeneric
05/2008 - 05/2008
2Multidrug Resistance-Associated Protein 2IBA
05/2007 - 12/2003
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
11/2005 - 11/2002
2LigandsIBA
09/2004 - 11/2002
1Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
01/2023
1Antihypertensive Agents (Antihypertensives)IBA
01/2023
1Inositol (Myoinositol)IBA
01/2023
1Immunoglobulin E (IgE)IBA
10/2020
1Triglycerides (Triacylglycerol)IBA
10/2019
1elcatoninIBA
10/2019
1Teriparatide (Parathar)FDA Link
10/2019
1Diphosphonates (Bisphosphonates)IBA
10/2019
1Bone Density Conservation AgentsIBA
10/2019
1Risedronic Acid (Actonel)FDA LinkGeneric
10/2019
1Glucagon (Glukagon)FDA Link
10/2019
1caffeic acidIBA
10/2014
1protocatechualdehydeIBA
06/2014
1Myosin-Light-Chain PhosphataseIBA
08/2013
1Hormones (Hormone)IBA
08/2013
1Fatty Acids (Saturated Fatty Acids)IBA
05/2013
1IronIBA
08/2012
1DecitabineFDA Link
04/2012
1Heavy MetalsIBA
01/2012
1ArsenicIBA
01/2012
1ChromiumIBA
01/2012
1ElementsIBA
01/2012
1CarbohydratesIBA
10/2010
1GlycosaminoglycansIBA
10/2010
1Monoclonal AntibodiesIBA
10/2010
1EpitopesIBA
10/2010
1Polysaccharides (Glycans)IBA
10/2010
1Biomarkers (Surrogate Marker)IBA
10/2010
1AntigensIBA
10/2010
1Heparitin Sulfate (Heparan Sulfate)IBA
10/2010
1Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA
03/2010
1Detergents (Detergent)IBA
03/2010

Therapy/Procedure

4Therapeutics
06/2014 - 10/2002
2Glycemic Control
01/2014 - 02/2007
2Chemoprevention
03/2010 - 08/2005
2Combination Drug Therapy (Combination Chemotherapy)
05/2008 - 05/2008
1Gastrectomy
04/2022
1Oral Administration
10/2020